ClinicalTrials.gg
Enrolling by invitationNCT05041309Updated Sep 21, 2026

Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies

An observational study in Solid and Hematological Malignancies and Autoimmune Diseases, sponsored by Kite, A Gilead Company. Enrolling by invitation at 91 sites in 14 countries. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 823 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 277 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Planned enrollment
25th of 157
1,500 · median 150
Started
2021
with 74 others
Observational
157 of 823
56 open now
Primary completion
2040-12
later than 267 of 274 live
Registered
618th of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 25th largest by planned enrollment of the 157 observational ones that give a count, is one of 75 that started in 2021, is one of 157 observational ones, reaches primary completion later than 267 of the 274 other live ones, and was the 618th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, anitocabtagene autoleucel, INT2104, KITE-512, ACLX-001, and ACLX002 in participants of Kite-sponsored interventional studies.

The primary objectives of this study are to:

  • Evaluate the incidence and severity of related SAEs, late-onset targeted AEs/SAEs suspected to be possibly related to gene-modified cell therapy, including neurologic disorders, new autoimmune disorders (which are distinct from the study-treated disease), hematologic disorders, serious infections, as well as any new malignancies (regardless of causality)
  • Evaluate the growth, development, and sexual maturity of pediatric and adolescent participants treated with gene-modified cell therapy.
03

Conditions studied

  • Solid and Hematological Malignancies
  • Autoimmune Diseases
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The participants who received an infusion of gene-modified cells and have not died, withdrawn consent, been withdrawn by the investigator, or been lost to follow-up at the time of transition from the completed parent study.

Eligibility criteria

Inclusion Criteria:

  • The individual must have been administered gene-modified cell therapy or completed the post-treatment follow-up period in the parent study, as applicable
  • The individual must understand and voluntarily sign an Form (ICF) or an Informed Assent Form prior to any study-related assessments or procedures being conducted
  • In the investigator's judgment, the individual is willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation

Exclusion Criteria: none

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Axicabtagene Ciloleucel (KTE-C19)

    All participants who previously received axicabtagene ciloleucel (KTE-C19) in the parent study will be enrolled in this cohort for long-term follow-up.

    Biological: Axicabtagene Ciloleucel

  • Brexucabtagene Autoleucel (KTE-X19)

    All participants who previously received brexucabtagene autoleucel (KTE-X19) in the parent study will be enrolled in this cohort for long-term follow-up.

    Biological: Brexucabtagene Autoleucel

  • Anitocabtagene autleucel

    All participants who previously received anitocabtagene autleucel in the parent study will be enrolled in this cohort for long-term follow-up.

    Biological: Anitocabtagene autleucel

  • KITE-753

    All participants who previously received KITE-753 in the parent study will be enrolled in this cohort for long-term follow-up.

    Biological: KITE-753

  • KITE-197

    All participants who previously received KITE-197 in the parent study will be enrolled in this cohort for long-term follow-up.

    Biological: KITE-197

  • KITE-363: Oncology Indication

    All participants who previously received KITE-363 for oncology indication in the parent study will be enrolled in this cohort for long-term follow-up.

    Biological: KITE-363

  • KITE-363: Autoimmune Indication

    All participants who previously received KITE-363 for autoimmune indication in the parent study will be enrolled in this cohort for long-term follow-up.

    Biological: KITE-363

  • INT2104

    All participants who previously received INT2104 in the parent study will be enrolled in this cohort for long-term follow-up.

    Biological: INT2104

  • KITE-512

    All participants who previously received KITE-512 in the parent study will be enrolled in this cohort for long-term follow-up.

    Biological: KITE-512

  • ACLX-001 (SPRX001 + ARC-T cells)

    All participants who previously received ACLX-001 in the parent study will be enrolled in this cohort for long-term follow-up.

    Biological: SPRX001 · Biological: ARC-T Cells

  • ACLX002 (SPRX002 + ARC-T cells)

    All participants who previously received ACLX-002 in the parent study will be enrolled in this cohort for long-term follow-up.

    Biological: SPRX002 · Biological: ARC-T Cells

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Late-onset Targeted Adverse Events (AEs)

    Targeted AEs include late-onset targeted AEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, and serious infections.

    Time frame: Up to 15 years

  2. Percentage of Participants Experiencing Late-onset Targeted Serious Adverse Events (SAEs)

    Targeted SAEs include late-onset targeted SAEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, and serious infections.

    Time frame: Up to 15 years

  3. Percentage of Participants With New Malignancies

    New malignancies regardless of causality includes time to development of the new malignancy, type, location, staging, and molecular mechanism (including testing for presence of the CAR transgene and (replication-competent retrovirus/replication-competent lentivirus (RCR/RCL)). Also to assess the occurrence of all related SAEs that do not fall under the umbrella of targeted events.

    Time frame: Up to 15 years

  4. Percentage of Participants Experiencing Related SAEs

    Adverse events which might be possibly related to the treatment drugs.

    Time frame: Up to 15 years

  5. Height of Pediatric and Adolescent Participants

    Time frame: Up to 15 years

  6. Weight of Pediatric and Adolescent Participants

    Time frame: Up to 15 years

  7. Sexual Maturation of Pediatric and Adolescent Participants Assessed by Tanner Pubertal Stage Scale Score

    The Tanner Pubertal Stage Scale is a measure of pubertal development (sexual maturation) in children and adolescents with components described for each sex, rated separately on a scale of stage one to stage five, with 1 for preadolescent and 5 for mature/adult.

    Time frame: Up to 15 years

Secondary outcomes

  1. Time to Subsequent Anticancer Therapies

    Time to subsequent anticancer therapies will be assessed only per regulatory request or sponsor needs.

    Time frame: Up to 15 years

  2. Survival Status Assessment

    Survival status will be assessed as the length of time from the participant's first dose date of study drug to death during the study due to any cause or last date of being alive during the study. Survival status will be assessed only per regulatory request or sponsor needs.

    Time frame: Up to 15 years

  3. Percentage of Participants With Cause of Death

    Time frame: Up to 15 years

  4. Overall Rate of Replication-competent RCR/RCL

    Time frame: Up to 15 years

  5. Percentage of Participants With Vector Integration Site(s) for RCR/RCL or Insertional Mutagenesis for Confirmed Events Related to the Cell Therapy Product

    Time frame: Up to 15 years

  6. Percentage of Participants With Status of Primary Malignant Disease

    Time frame: Up to 15 years

07

Study locations

91 sites
08

References and documents

Publications

  • Munoz J, Locke FL, Reagan PM, Goy A, Jacobson CA, Hill BT, Timmerman JM, Flinn IW, Miklos DB, Pagel JM, Kersten MJ, Forcade E, Topp MS, Houot R, Beitinjaneh A, Zheng D, Chang M, Zhang W, Shen RR, Khalid RD, Kloos I, Wang ML. Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2. J Hematol Oncol. 2026 Apr 27;19(1):39. doi: 10.1186/s13045-026-01797-4. PubMed 42036693 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2040, 228 months after the start.

Of 186 observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 228 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2021
First posted
Sep 13, 2021
StartActual
Dec 15, 2021
Primary completionEst.
Dec 2040
CompletionEst.
Dec 2040
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05041309
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Dec 15, 2021
Primary completion
Dec 2040 (estimated)
Completion
Dec 2040 (estimated)
Last update
Sep 21, 2026

Study contacts

Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion